Hepatitis C virus virology and new treatment targets

References

• Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med.292(15), 767–770 (1975).
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science244(4902), 359–362 (1989).
   PubMed Web of Science ®Google Scholar
• Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med.321(22), 1494–1500 (1989).
   PubMed Web of Science ®Google Scholar
• Alter HJ, Houghton M. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat. Med.6, 1082–1086 (2000).
   PubMed Web of Science ®Google Scholar
• Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol.44(1), 20–29 (2004).
   PubMed Web of Science ®Google Scholar
• Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet355(9207), 887–891 (2000).
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr. Infect. Dis. J.24(9), 755–760 (2005).
   PubMed Web of Science ®Google Scholar
• Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology43(5), 915–922 (2006).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol.13(17), 2436–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C. Hepatology26(3 Suppl. 1), 62–65 (1997).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Teuber G, Lee JH, Ruster B, Roth WK. Risk factors for the transmission of hepatitis C. J. Hepatol.24(2), 3–10 (1996).
   PubMedGoogle Scholar
• Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med.334(26), 1691–1696 (1996).
   PubMed Web of Science ®Google Scholar
• Touzet S, Kraemer L, Colin C et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research). Eur. J. Gastroenterol. Hepatol.12(6), 667–678 (2000).
   PubMed Web of Science ®Google Scholar
• Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case–control study. Gastroenterology116(4), 893–899 (1999).
   PubMed Web of Science ®Google Scholar
• Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ317(7156), 437–441 (1998).
   PubMed Web of Science ®Google Scholar
• Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet356(9233), 904–907 (2000).
   PubMed Web of Science ®Google Scholar
• Prieto M, Olaso V, Verdu C et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology22(2), 413–417 (1995).
   PubMedGoogle Scholar
• Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology21(2), 285–290 (1995).
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Morales R, Spinzi G et al. interferon α treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology27(3), 853–856 (1998).
   PubMed Web of Science ®Google Scholar
• Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am. J. Gastroenterol.95(6), 1545–1550 (2000).
   PubMed Web of Science ®Google Scholar
• Wietzke-Braun P, Braun F, Schott P, Ramadori G. Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection? World J. Gastroenterol.9(4), 745–750 (2003).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis.15, 64–69 (1995).
   PubMed Web of Science ®Google Scholar
• Degos F, Christidis C, Ganne-Carrie N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut47(1), 131–136 (2000).
   PubMed Web of Science ®Google Scholar
• Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology28(3), 823–830 (1998).
   PubMed Web of Science ®Google Scholar
• Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med.6(5), 578–582 (2000).
   PubMed Web of Science ®Google Scholar
• Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J. Hepatol.30(6), 979–983 (1999).
   PubMed Web of Science ®Google Scholar
• Robertson B, Myers G, Howard C et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol.143(12), 2493–2503 (1998).
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology42(4), 962–973 (2005).
   PubMed Web of Science ®Google Scholar
• Laperche S, Lunel F, Izopet J et al. Comparison of hepatitis C virus NS5b and 5´ noncoding gene sequencing methods in a multicenter study. J. Clin. Microbiol.43(2), 733–739 (2005).
   PubMed Web of Science ®Google Scholar
• Laperche S, Saune K, Deny P et al. Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies. J. Clin. Microbiol.44(2), 614–616 (2006).
   PubMed Web of Science ®Google Scholar
• Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol.48(1), 148–162 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol.3(10 Suppl. 2), S97–S101 (2005).
   PubMed Web of Science ®Google Scholar
• Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int. J. Infect. Dis.10(4), 272–277 (2006).
   PubMed Web of Science ®Google Scholar
• Rustgi VK. The epidemiology of hepatitis C infection in the United States. J. Gastroenterol.42(7), 513–521 (2007).
   PubMed Web of Science ®Google Scholar
• Huang L, Koziel MJ. Immunology of hepatitic C virus infection. Curr. Opin. Gastroenterol.16, 558–564 (2000).
   PubMed Web of Science ®Google Scholar
• Schweyer S, Mihm S, Radzun HJ, Hartmann H, Fayyazi A. Liver infiltrating T lymphocytes express interferon γ and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut46(2), 255–259 (2000).
   PubMed Web of Science ®Google Scholar
• Baroni GS, Pastorelli A, Manzin A et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver19(3), 212–219 (1999).
   PubMedGoogle Scholar
• Ksontini R, Colagiovanni DB, Josephs MD et al. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J. Immunol.160(8), 4082–4089 (1998).
   PubMed Web of Science ®Google Scholar
• Chen YL, Yu CK, Lei HY. Propionibacterium acnes induces acute TNFα-mediated apoptosis of hepatocytes followed by inflammatory T-cell-mediated granulomatous hepatitis in mice. J. Biomed. Sci.6(5), 349–356 (1999).
   PubMed Web of Science ®Google Scholar
• Billerbeck E, Thimme R. CD8+ regulatory T cells in persistent human viral infections. Hum. Immunol.69(11), 771–775 (2008).
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Szabo G. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don’t. J. Leukoc. Biol.84(3), 614–622 (2008).
   PubMed Web of Science ®Google Scholar
• Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern. Med.45(4), 183–191 (2006).
   PubMed Web of Science ®Google Scholar
• Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver Dis.12(3), 713–726, xi (2008).
   PubMed Web of Science ®Google Scholar
• Neuman MG, Sha K, Esguerra R et al. Inflammation and repair in viral hepatitis C. Dig. Dis. Sci.53(6), 1468–1487 (2008).
   PubMed Web of Science ®Google Scholar
• Ramadori G, Saile B. Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology127(3), 997–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab. Invest.84(2), 153–159 (2004).
   PubMed Web of Science ®Google Scholar
• Wietzke P, Braun F, Ringe B, Ramadori G. Interferon α-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation. Transplant. Proc.32(7), 2539–2542 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen J. The scientific challenge of hepatitis C. Science285(5424), 26–30 (1999).
   PubMed Web of Science ®Google Scholar
• Choo QL, Richman KH, Han JH et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA88(6), 2451–2455 (1991).
   PubMed Web of Science ®Google Scholar
• Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl Acad. Sci. USA88(13), 5547–5551 (1991).
   PubMed Web of Science ®Google Scholar
• Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol.68(6), 3631–3641 (1994).
   PubMed Web of Science ®Google Scholar
• Shimotohno K, Tanji Y, Hirowatari Y, Komoda Y, Kato N, Hijikata M. Processing of the hepatitis C virus precursor protein. J. Hepatol.22(1), 87–92 (1995).
   PubMed Web of Science ®Google Scholar
• Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J. Virol.68(4), 2731–2734 (1994).
   PubMed Web of Science ®Google Scholar
• Hijikata M, Mizushima H, Akagi T et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol.67(8), 4665–4675 (1993).
   PubMed Web of Science ®Google Scholar
• Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc. Natl Acad. Sci. USA90(22), 10583–10587 (1993).
   PubMed Web of Science ®Google Scholar
• Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol.67(7), 4017–4026 (1993).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol.67(7), 3835–3844 (1993).
   PubMed Web of Science ®Google Scholar
• Wang C, Siddiqui A. Structure and function of the hepatitis C virus internal ribosome entry site. Curr. Top. Microbiol. Immunol.203, 99–115 (1995).
   PubMed Web of Science ®Google Scholar
• Irshad M, Dhar I. Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. Med. Princ. Pract.15(6), 405–416 (2006).
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev.5(6), 453–463 (2007).
   Google Scholar
• Boulant S, Montserret R, Hope RG et al. Structural determinants that target the hepatitis C virus core protein to lipid droplets. J. Biol. Chem.281(31), 22236–22247 (2006).
   PubMed Web of Science ®Google Scholar
• Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut55(1), 123–130 (2006).
   PubMed Web of Science ®Google Scholar
• Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology348(1), 1–12 (2006).
   PubMed Web of Science ®Google Scholar
• Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol.87(Pt 5), 1075–1084 (2006).
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med.11(7), 791–796 (2005).
   PubMed Web of Science ®Google Scholar
• Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol.12(11), 517–523 (2002).
   PubMed Web of Science ®Google Scholar
• Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem.281(35), 25177–25183 (2006).
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science282(5390), 938–941 (1998).
   PubMed Web of Science ®Google Scholar
• Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J.21(19), 5017–5025 (2002).
   PubMed Web of Science ®Google Scholar
• Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem.278(42), 41003–41012 (2003).
   PubMed Web of Science ®Google Scholar
• Gardner JP, Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA100(8), 4498–4503 (2003).
   PubMed Web of Science ®Google Scholar
• Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem.278(22), 20358–20366 (2003).
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA96(22), 12766–12771 (1999).
   PubMed Web of Science ®Google Scholar
• Monazahian M, Bohme I, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol.57(3), 223–229 (1999).
   PubMed Web of Science ®Google Scholar
• Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J. Virol.76(8), 3720–3730 (2002).
   PubMed Web of Science ®Google Scholar
• Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J. Virol.68(8), 5063–5073 (1994).
   PubMed Web of Science ®Google Scholar
• Clarke D, Griffin S, Beales L et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J. Biol. Chem.281(48), 37057–37068 (2006).
   PubMed Web of Science ®Google Scholar
• Sakai A, Claire MS, Faulk K et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl Acad. Sci. USA100(20), 11646–11651 (2003).
   PubMed Web of Science ®Google Scholar
• Griffin SD, Beales LP, Clarke DS et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett.535(1–3), 34–38 (2003).
   PubMed Web of Science ®Google Scholar
• Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog.3(7), e103 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Q, Bhat RA, Prince AM, Zhang P. The hepatitis C virus NS2 protein generated by NS2-3 autocleavage is required for NS5A phosphorylation. Biochem. Biophys. Res. Commun.254(3), 572–577 (1999).
   PubMed Web of Science ®Google Scholar
• Dumoulin FL, von dem Bussche A, Li J et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology305(2), 260–266 (2003).
   PubMed Web of Science ®Google Scholar
• Kaukinen P, Sillanpaa M, Kotenko S et al. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol. J.3, 66 (2006).
   PubMedGoogle Scholar
• Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science309(5734), 623–626 (2005).
   PubMed Web of Science ®Google Scholar
• Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol.81(16), 8374–8383 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell87(2), 343–355 (1996).
   PubMed Web of Science ®Google Scholar
• Love RA, Parge HE, Wickersham JA et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell87(2), 331–342 (1996).
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature436(7053), 933–938 (2005).
   PubMed Web of Science ®Google Scholar
• Foy E, Li K, Wang C et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science300(5622), 1145–1148 (2003).
   PubMed Web of Science ®Google Scholar
• Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature437(7062), 1167–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Sen GC, Sarkar SN. Hitching RIG to action. Nat. Immunol.6(11), 1074–1076 (2005).
   PubMed Web of Science ®Google Scholar
• Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA102(49), 17717–17722 (2005).
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA102(8), 2992–2997 (2005).
   PubMed Web of Science ®Google Scholar
• Elazar M, Liu P, Rice CM, Glenn JS. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J. Virol.78(20), 11393–11400 (2004).
   PubMed Web of Science ®Google Scholar
• Paredes AM, Blight KJ. A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication. J. Virol.82(21), 10671–10683 (2008).
   PubMed Web of Science ®Google Scholar
• Jones DM, Patel AH, Targett-Adams P, McLauchlan J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol.83(5), 2163–2177 (2009).
   PubMed Web of Science ®Google Scholar
• Penin F, Brass V, Appel N et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem.279(39), 40835–40843 (2004).
   PubMed Web of Science ®Google Scholar
• Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol.69(7), 3980–3986 (1995).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem.279(47), 48576–48587 (2004).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature435(7040), 374–379 (2005).
   PubMed Web of Science ®Google Scholar
• Gale M Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol.18(9), 5208–5218 (1998).
   PubMed Web of Science ®Google Scholar
• Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol.10(2–3), 157–162 (1998).
   PubMedGoogle Scholar
• Gale MJ Jr, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology230(2), 217–227 (1997).
   PubMed Web of Science ®Google Scholar
• Appel N, Pietschmann T, Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J. Virol.79(5), 3187–3194 (2005).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog.4(3), e1000032 (2008).
   PubMed Web of Science ®Google Scholar
• Appel N, Zayas M, Miller S et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog.4(3), e1000035 (2008).
   PubMed Web of Science ®Google Scholar
• Ivashkina N, Wolk B, Lohmann V et al. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J. Virol.76(24), 13088–13093 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt-Mende J, Bieck E, Hugle T et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem.276(47), 44052–44063 (2001).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res.63, 71–180 (2004).
   PubMed Web of Science ®Google Scholar
• Bressanelli S, Tomei L, Roussel A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA96(23), 13034–13039 (1999).
   PubMed Web of Science ®Google Scholar
• Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol.6(10), 937–943 (1999).
   PubMedGoogle Scholar
• Otto GA, Puglisi JD. The pathway of HCV IRES-mediated translation initiation. Cell119(3), 369–380 (2004).
   PubMed Web of Science ®Google Scholar
• Pestova TV, Kolupaeva VG, Lomakin IB et al. Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl Acad. Sci. USA98(13), 7029–7036 (2001).
   PubMed Web of Science ®Google Scholar
• Ji H, Fraser CS, Yu Y, Leary J, Doudna JA. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc. Natl Acad. Sci. USA101(49), 16990–16995 (2004).
   PubMed Web of Science ®Google Scholar
• Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology44(3), 527–535 (2006).
   PubMed Web of Science ®Google Scholar
• Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature446(7137), 801–805 (2007).
   PubMed Web of Science ®Google Scholar
• Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann. Intern. Med.129(4), 323–326 (1998).
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ315(7106), 453–458 (1997).
   PubMed Web of Science ®Google Scholar
• Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost–effectiveness analysis. Ann. Intern. Med.133(9), 665–675 (2000).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med.321(22), 1506–1510 (1989).
   PubMed Web of Science ®Google Scholar
• Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med.321(22), 1501–1506 (1989).
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology24(4), 778–789 (1996).
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V et al. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med.339(21), 1493–1499 (1998).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis GL et al. Impact of interferon α2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology32(5), 1131–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann. Intern. Med.131(9), 696–701 (1999).
   PubMed Web of Science ®Google Scholar
• Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-α2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low γ-GT/ALT ratio. Dig. Dis. Sci.41(6), 1256–1264 (1996).
   PubMed Web of Science ®Google Scholar
• Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R. Ratio of serum γ-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-α in chronic HCV infection. J. Med. Virol.58(3), 227–234 (1999).
   PubMed Web of Science ®Google Scholar
• Fukuma T, Enomoto N, Marumo F, Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology28(4), 1147–1153 (1998).
   PubMed Web of Science ®Google Scholar
• Mihm S, Monazahian M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon-αsensitivity-determining region variability in RNA- dependent protein kinase-mediated cellular antiviral responses. J. Med. Virol.61(1), 29–36 (2000).
   PubMed Web of Science ®Google Scholar
• Wietzke-Braun P, Maouzi AB, Manhardt LB, Bickeboller H, Ramadori G, Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol.18(9), 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Wietzke-Braun P, Manhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J. Gastroenterol.13(31), 4224–4229 (2007).
   PubMed Web of Science ®Google Scholar
• Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver19(4), 348–353 (1999).
   PubMedGoogle Scholar
• Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-α-2A plus ribavirin. Gastroenterology130(4), 1086–1097 (2006).
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-α2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology131(2), 451–460 (2006).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon α2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol.44(1), 97–103 (2006).
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N et al. Peginterferon α2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.352(25), 2609–2617 (2005).
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology129(2), 522–527 (2005).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR et al. Peginterferon α-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.357(2), 124–134 (2007).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon α2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol.40(6), 993–999 (2004).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med.359(23), 2429–2441 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS Jr, Freilich B et al. Peginterferon α2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology46(4), 971–981 (2007).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140(5), 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol.41(1), 17–27 (2006).
   PubMed Web of Science ®Google Scholar
• Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA95(26), 15623–15628 (1998).
   PubMed Web of Science ®Google Scholar
• Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev. Sci. Tech.17(1), 220–230 (1998).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell. Microbiol.8(6), 907–922 (2006).
   PubMed Web of Science ®Google Scholar
• Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol.82(Pt 4), 723–733 (2001).
   PubMed Web of Science ®Google Scholar
• Meier V, Mihm S, Ramadori G. mxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-α. J. Med. Virol.62(3), 318–326 (2000).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology46(5), 1548–1563 (2007).
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA105(19), 7034–7039 (2008).
   PubMed Web of Science ®Google Scholar
• Meier V, Mihm S, Ramadori G. Interferon-α therapy does not modulate hepatic expression of classical type I interferon inducible genes. J. Med. Virol.80(11), 1912–1918 (2008).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-α in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology43(5), 961–972 (2006).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology46(4), 999–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Mihm S, Frese M, Meier V et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest.84(9), 1148–1159 (2004).
   PubMed Web of Science ®Google Scholar
• Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J. Virol.75(3), 1332–1338 (2001).
   PubMed Web of Science ®Google Scholar
• Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am. J. Pathol.160(2), 641–654 (2002).
   PubMed Web of Science ®Google Scholar
• MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J. Med. Virol.70(2), 219–227 (2003).
   PubMed Web of Science ®Google Scholar
• Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology36(5 Suppl. 1), S185–S194 (2002).
   Google Scholar
• Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology45(3), 579–587 (2007).
   PubMed Web of Science ®Google Scholar
• Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon α2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral Hepat.13(6), 409–414 (2006).
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Andreone P, Craxi A. interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol.34(4), 593–602 (2001).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther.15(5), 689–698 (2001).
   PubMed Web of Science ®Google Scholar
• Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology37(1), 60–64 (2003).
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology125(1), 80–88 (2003).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Fouly AE, Kamel RR et al. Peginterferon α2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology130(3), 632–638 (2006).
   PubMed Web of Science ®Google Scholar
• Santantonio T, Fasano M, Sinisi E et al. Efficacy of a 24-week course of PEG-interferon α2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol.42(3), 329–333 (2005).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology43(5), 923–931 (2006).
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon α2b in cell culture. Hepatol. Res.37(11), 941–947 (2007).
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Yoshida EM et al. A Phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin–interferon α fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol.44(4), 671–678 (2006).
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS et al. A Phase I/II study evaluating escalating doses of recombinant human albumin–interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antivi. Ther.11(1), 35–45 (2006).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y et al. Albinterferon α2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology48(2), 407–417 (2008).
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Marotta P et al. Safety and antiviral activity of albinterferon α2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin. Gastroenterol. Hepatol.6(6), 701–706 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Rustgi V, Balan V et al. Safety and antiviral activity of albinterferon α2b in prior interferon nonresponders with chronic hepatitis C. Clin. Gastroenterol. Hepatol.7(2), 212–218 (2009).
   PubMed Web of Science ®Google Scholar
• Novozhenov V, Zakharova N, Vinogradova E et al. Phase 2 study of ω interferon αlone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J. Hepatol.46(Suppl. 1), S8 (2007).
   Google Scholar
• De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG. Novel controlled-release Lemna-derived IFN-α2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a Phase I clinical trial. J. Interferon Cytokine Res.28(2), 113–122 (2008).
   PubMed Web of Science ®Google Scholar
• Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J. Antimicrob. Chemother.52(4), 543–546 (2003).
   PubMed Web of Science ®Google Scholar
• Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother.47(1), 426–431 (2003).
   PubMed Web of Science ®Google Scholar
• Lin CC, Lourenco D, Xu G, Yeh LT. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother.48(5), 1872–1875 (2004).
   PubMed Web of Science ®Google Scholar
• Gish RG, Arora S, Rajender Reddy K et al. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon α-2a: a randomized, Phase 2 study. J. Hepatol.47(1), 51–59 (2007).
   PubMed Web of Science ®Google Scholar
• Pockros P, Jacobsen IM, Bacon BR et al. Taribavirin exposure analysis from a previous Phase 3 trial correlates with Phase 2b weight based dosing interim results. Hepatology48(Suppl. 1), 1857A (2008).
   Google Scholar
• Hinrichsen H, Benhamou Y, Wedemeyer H et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology127(5), 1347–1355 (2004).
   PubMed Web of Science ®Google Scholar
• Lu L, Pilot-Matias TJ, Stewart KD et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother.48(6), 2260–2266 (2004).
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology131(4), 997–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology132(5), 1767–1777 (2007).
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon α-2a in patients with hepatitis C. Hepatology46(3), 640–648 (2007).
   PubMed Web of Science ®Google Scholar
• Les L. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C. Gastroenterology132(7), 2283–2284 (2007).
   PubMed Web of Science ®Google Scholar
• Forns X, Marcellin P, Goeser T et al. Phase 2 study of telaprevir administered q8h or q12h with peginterferon-α-2a or -α-2b and ribavirin in treatment-naïve subjects with genotype 1 hepatitis C: week 4 interim results. Hepatology48(Suppl. 1), 1854A (2008).
   Google Scholar
• Shiffman ML, Berg T, Poordad F et al. A study of telaprevir combined with peginterferon-α-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-α-2a and ribavirin treatment: interim analysis. Hepatology48(Suppl. 1), 1852A (2008).
   Google Scholar
• Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr. Opin. Investig. Drugs10(2), 181–189 (2009).
   PubMed Web of Science ®Google Scholar
• Malcolm BA, Liu R, Lahser F et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob. Agents Chemother.50(3), 1013–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α2b for genotype 1 nonresponders. Gastroenterology132(4), 1270–1278 (2007).
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz E, McCone J et al. HCV SPRINT-1: boceprevir plus peginterferon α2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology48(Suppl. 1), LB16 (2008).
   Google Scholar
• Seiwert SD, Andrews SW, Jiang Y et al. Preclinical characteristics of the HCV NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother.52(12), 4432–4441 (2008).
   PubMed Web of Science ®Google Scholar
• Rajagopalan R, Misialek S, Stevens S et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Forestier N, Larrey D, Guyader D et al. treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a Phase 1B multiple ascending dose (MAD) study. Hepatology48(Suppl. 1), 1847A (2008).
   Google Scholar
• Tan H, Rajyaguru S, Wu T et al. Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5b inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Hepatology48(Suppl. 1), 1885A (2008).
   PubMed Web of Science ®Google Scholar
• Yang W, Zhao Y, Fabrycki J et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob. Agents Chemother.52(6), 2043–2052 (2008).
   PubMed Web of Science ®Google Scholar
• Manns MP, Bourliere M, Benhamou Y et al. Safety and antiviral activity of bi201335, a new HCV NS3 protease inhibitor, in treatmentnaive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon α 2a (P) and ribavirin (R). Hepatology48(Suppl. 1), 1849A (2008).
   Google Scholar
• Lin TI, Lenz O, Fanning G et al.In vitro activity and pre-clinical profile of TMC435350, a potent HCV protease inhibitor. Antimicrob. Agents Chemother. (2009) (Epub ahead of print).
   Google Scholar
• Verloes R, Farha KA, van Vliet A et al. results of a Phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology46(Suppl. 1), 1318A (2007).
   Google Scholar
• Reesink H, Verloes R, Abou Farha K et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a Phase I study. J. Hepatol.48(Suppl. 2), S28 (2008).
   PubMed Web of Science ®Google Scholar
• Godofsky E, Afdhal N, Rustgi V et al. First clinical results for a novel antiviral treatment for hepatitis C: a Phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283. J. Hepatol.40(Suppl. 1), S35 (2004).
   Web of Science ®Google Scholar
• Afdhal N, O Brien C, Godofsky E et al. Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: week 24 results. J. Hepatol.44(Suppl. 2), S19 (2006).
   PubMed Web of Science ®Google Scholar
• Afdhal N, O’Brien C, Godofsky E et al. Valopicitabine (NM283), alone or with peg-interferon, compared to peg interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results. J. Hepatol.46(Suppl. 1), S5 (2007).
   Google Scholar
• Klumpp K, Leveque V, Le Pogam S et al. The novel nucleoside analog R1479 (4´-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem.281(7), 3793–3799 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts SK, Cooksley G, Dore GJ et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology48(2), 398–406 (2008).
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Nelson D, Godofsky E et al. R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology48(2), 385–397 (2008).
   PubMed Web of Science ®Google Scholar
• Villano SA, Raible D, Harper D et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon α2b in treatment-naive patients with chronic HCV. J. Hepatol.46(Suppl. 1), S24 (2007).
   Web of Science ®Google Scholar
• Bavisotto L, Wang CC, Jacobsen IM et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology46(4), 49A (2007).
   Google Scholar
• Erhardt A, Wedemeyer H, Benhamou Y et al. Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J. Hepatol.46(Suppl. 1), S222 (2007).
   PubMed Web of Science ®Google Scholar
• Li H, Tatlock J, Linton A et al. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. (2009) (In Press).
   Google Scholar
• Hammond J, Rosario MC, Wagner F et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. Hepatology48(Suppl. 1), LB11 (2008).
   Google Scholar
• Rahimy MH, Crowley CA, Freddo L, Sergeeva MV, Golec B. Results of a Phase I safety, tolerability and pharmacokinetic study of ANA598, a nonnucleoside NS5B polymerase inhibitor, in healthy volunteers. Hepatology48(Suppl. 1), LB13 (2008).
   Google Scholar
• Nettles R, Chien C, Chun E et al. BMS-790052 is a First-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology48(Suppl. 1), LB12 (2008).
   Google Scholar
• Kaita K, Yoshida E, Kunimoto D et al. Proof of concept study of celgosivir in combination with peginterferon α2b and ribavirin in chronic hepatitis c genotype-1 non-responder patients. J. Hepatol.46(Suppl. 1), S56–S57 (2007).
   Google Scholar
• Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science226(4674), 544–547 (1984).
   PubMed Web of Science ®Google Scholar
• Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. Cell66(4), 807–815 (1991).
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology129(3), 1031–1041 (2005).
   PubMed Web of Science ®Google Scholar
• Watashi K, Ishii N, Hijikata M et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell19(1), 111–122 (2005).
   PubMed Web of Science ®Google Scholar
• Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol.81(11), 5829–5840 (2007).
   PubMed Web of Science ®Google Scholar
• Paeshuyse J, Kaul A, De Clercq E et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology43(4), 761–770 (2006).
   PubMed Web of Science ®Google Scholar
• Ishii N, Watashi K, Hishiki T et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol.80(9), 4510–4520 (2006).
   PubMed Web of Science ®Google Scholar
• Heitman J, Cullen BR. Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? Mol. Cell19(2), 145–146 (2005).
   PubMed Web of Science ®Google Scholar
• Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun.343(3), 879–884 (2006).
   PubMed Web of Science ®Google Scholar
• Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev. Med. Virol.17(4), 245–252 (2007).
   PubMed Web of Science ®Google Scholar
• Inoue K, Umehara T, Ruegg UT et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology45(4), 921–928 (2007).
   PubMed Web of Science ®Google Scholar
• Flisiak R, Horban A, Gallay P et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology47(3), 817–826 (2008).
   PubMed Web of Science ®Google Scholar
• Herrmann E, Flisiak R, Horban A et al. Viral kinetics during 14-day treatment with DEBIO-025 demonstrate efficient blocking of viral replication in different HCV genotypes without signs of emerging viral resistance. J. Hepatol.46(Suppl. 1), S40 (2007).
   Google Scholar